COST-UTILITY ANALYSIS OF OMALIZUMAB COMPARED WITH STANDARD THERAPY IN PATIENTS OVER TWELVE YEARS OLD WITH SEVERE ASTHMA FROM THE COLOMBIAN HEALTH SYSTEM PERSPECTIVE

被引：0

作者：

Ariza, J. G. ^{[1
]}

Acosta, T. ^{[2
]}

Pinzon, J. F. ^{[1
]}

机构：

[1] Novartis Corp, Bogota, Colombia

[2] Univ La Sabana, Bogota, Colombia

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.jval.2012.03.311

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A56 / A56

页数：1

共 39 条

[31] Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: A cost-utility analysis from the perspective of the Veterans Affairs health care system
Yeh, Wei-Shi
Armstrong, Edward P.
Skrepnek, Grant H.
Malone, Daniel C.
PHARMACOTHERAPY, 2007, 27 (06): : 813 - 824
[32] Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective
Angulo, J. C.
Sanchez-Ballester, F.
Peral, C.
Rejas, J.
Ramos, J.
Snedecor, S. J.
Sudharshan, L.
Liu, S.
Luo, X.
ACTAS UROLOGICAS ESPANOLAS, 2016, 40 (08): : 513 - 522
[33] Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective
Zhou, Keruo
Zhang, Min
Zuo, Chenyu
Xie, Xiazhen
Xuan, Jianwei
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1018 - 1026
[34] A Cost-Effectiveness Study of Stereotactic-Body Radiation Therapy Compared to Surgery in Patients with Early NonSmall Cell Lung Cancer, from the Perspective of the Brazilian Private Health-Care System
Santos, M. A.
Oliveira e Silva, L. F.
Reis Neto, J. P.
Bernardi, B.
Lee, D.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E389 - E389
[35] COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH ASYMPTOMATIC TO MILD HEART FAILURE BASED ON THE EUROPEAN COHORT OF THE REVERSE STUDY FROM THE SPANISH HEALTH SYSTEM PERSPECTIVE
Quesada, A.
Almenar, L.
Diaz Molina, B.
Crespo, C.
Marti, B.
Mealing, S.
Linde, C.
Daubert, C.
VALUE IN HEALTH, 2011, 14 (07) : A249 - A249
[36] A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
McNamara, S.
Moore, L.
Ray, J.
VALUE IN HEALTH, 2010, 13 (07) : A269 - A269
[37] BUDGET IMPACT ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYA') VERSUS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE FROM PUBLIC HEALTH SYSTEM PERSPECTIVE IN CHILE
Balmaceda, C.
Abbott, T.
Espinoza, M. A.
VALUE IN HEALTH, 2020, 23 : S354 - S354
[38] BRIGATINIB COMPARED WITH CRIZOTINIB AND ALECTINIB IN PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASES AT DIAGNOSIS: A COST-EFFECTIVENESS ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Genov, I
Mendes da Silva, B.
Lanchoti Fiori, G. M.
Villas Boas, B.
Teixeira Chadid, T.
Regis, C.
VALUE IN HEALTH, 2021, 24 : S31 - S32
[39] Nab-paclitaxel weekly or Q3w compared to docetaxel Q3w as first-line therapy in patients with metastatic breast cancer (MBC): an economic analysis of a prospective randomized trial from the perspective of the German health care system
Dranitsaris, G.
Schoening, T.
EJC SUPPLEMENTS, 2009, 7 (02): : 280 - 280

← 1 2 3 4 →